Citi analyst David Lebowitz raised the firm’s price target on Crinetics (CRNX) to $74 from $70 and keeps a Buy rating on the shares following the Q3 report. Crinetics is building a “powerful endocrinology portfolio and look forward to multiple, inflection-worthy catalysts in the coming year,” the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRNX: